Investigating the effects of a specific HIV treatment on maternal and child health
Obesogenic origins of maternal and child metabolic health involving dolutegravir (ORCHID)
This study is looking at how the HIV medication Dolutegravir affects the health of pregnant women and their babies, and it’s for pregnant women with HIV as well as those without HIV, to help understand how this treatment might influence weight and health during pregnancy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10850865 on NIH RePORTER |
What this research studies
This research focuses on understanding how the antiretroviral drug Dolutegravir (DTG) affects the metabolic health of pregnant women living with HIV and their children. The study will enroll 1,900 pregnant women in their first trimester, including those starting DTG treatment and those continuing from before pregnancy, as well as women without HIV. Researchers will track the health outcomes of these women and their children over two years to assess the impact of DTG on weight gain and obesity-related health issues. The study aims to provide insights into how HIV treatment may influence maternal and child health during a critical period.
Who could benefit from this research
Good fit: Ideal candidates for participation include pregnant women in their first trimester, particularly those living with HIV who are starting or continuing DTG treatment.
Not a fit: Patients who are not pregnant or those who do not have HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved health outcomes for mothers and children affected by HIV, particularly regarding weight management and metabolic health.
How similar studies have performed: Previous research has indicated potential links between antiretroviral treatments and weight gain, but this specific investigation into DTG's effects during pregnancy is relatively novel.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Abrams, Elaine Janine — Columbia University Health Sciences
- Study coordinator: Abrams, Elaine Janine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.